Literature DB >> 22512840

Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo.

K Ezzedine1, A Diallo, C Léauté-Labrèze, J Seneschal, K Boniface, M Cario-André, S Prey, F Ballanger, F Boralevi, T Jouary, D Mossalayi, A Taieb.   

Abstract

BACKGROUND: Limited epidemiological data exist that compare clinical features of pre- and post-pubertal nonsegmental vitiligo.
OBJECTIVES: To compare factors associated with pre- and post-pubertal onset vitiligo. PATIENTS AND METHODS: A prospective observational study was conducted of patients with vitiligo attending the clinic between 1 January 2006 and 1 July 2011. The Vitiligo European Task Force questionnaire was completed for each patient and thyroid function and antithyroid antibodies were screened. Other forms of vitiligo (segmental, focal, mucosal, not classifiable) were excluded.
RESULTS: A total of 679 patients were included; 422 had post-pubertal and 257 pre-pubertal onset of vitiligo. Vitiligo universalis was seen only in post-pubertal onset. In univariate analysis, there was no significant statistical difference for sex, Koebner phenomenon or disease activity between both groups; thyroid disease or presence of thyroid antibodies was more frequent in post-pubertal onset [odds ratio (OR) 0·31, P < 0·003] whereas atopic dermatitis was more often associated with or preceding pre-pubertal onset (OR 2·42, P = 0·006). In multivariate analysis, halo naevi, family history of vitiligo, premature hair greying, atopic dermatitis and previous episode of spontaneous repigmentation were independently associated with pre-pubertal onset. In contrast, stress as onset factor, personal history of thyroid disease and acrofacial type were associated with post-pubertal onset.
CONCLUSIONS: Pre-pubertal onset vitiligo is strongly associated with personal and family history of atopy, suggesting that the predisposing immune background in vitiligo is not limited to autoimmunity, as also noted in alopecia areata. This study also suggests reconsidering the epidemiological data on sex ratio in vitiligo.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2012        PMID: 22512840     DOI: 10.1111/j.1365-2133.2012.11002.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  POLYGLANDULAR AUTOIMMUNE SYNDROME ASSOCIATED WITH MULTIPLE AUTOIMMUNE CONDITIONS AND ATOPIC DERMATITIS - AN UNUSUAL MANIFESTATION OF A POLYAUTOIMMUNITY PHENOTYPE.

Authors:  A M Forsea; C Mihai; T Predescu; I Tudose; I Margaritescu; C Giurcaneanu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

3.  Adult Onset Vitiligo: Multivariate Analysis Suggests the Need for a Thyroid Screening.

Authors:  L Lazzeri; R Colucci; A Cammi; F Dragoni; S Moretti
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

4.  Prepubertal and postpubertal vitiligo: a multivariate comparative study in 375 patients.

Authors:  Huma Khurrum; Khalid M AlGhamdi
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

5.  Factors Associated with Development of Vitiligo in Patients with Halo Nevus.

Authors:  Hui Zhou; Liang-Cai Wu; Mu-Kai Chen; Qi-Man Liao; Ren-Xiang Mao; Jian-De Han
Journal:  Chin Med J (Engl)       Date:  2017-11-20       Impact factor: 2.628

6.  Variations in TAP1 and PSMB9 Genes Involved in Antigen Processing and Presentation Increase the Risk of Vitiligo in the Saudi Community.

Authors:  Ahmad H Mufti; Imad A AlJahdali; Nasser A Elhawary; Samar N Ekram; Iman Abumansour; Ikhlas A Sindi; Hind Naffadi; Ezzeldin N Elhawary; Najiah M Alyamani; Ghydda Alghamdi; Wafaa Alosaimi; Ghufran Rawas; Amaal Alharbi; Mohammed T Tayeb
Journal:  Int J Gen Med       Date:  2021-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.